About this trial
To assess the prevalence and severity of frailty in patients undergoing LAAC, as well as its association to peri-procedural and long-term outcomes and quality of life.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Transcatheter LAAC with any approved device
Age ≥18 years old
Disqualifiers
Unable to provide informed consent
Severe neuropsychiatric impairment
Trial population
Patients ≥18 years old undergoing Transcatheter LAAC with any approved device
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Prevalence of frailty
Evaluated with Clinical Frailty Scale (CFS) 9-point scale (1-Very fit to 9-Terminally ill)
Prevalence of frailty
Evaluated with Essential Frailty Toolset (EFT) (Scored 0 (least frail) to 5 (most frail)
Rate of all-cause mortality
Rate of ischemic events
Stroke
Secondary outcomes
Rate of All-cause mortality
Rate of ischemic events
Ischemic stroke or peripheral embolism
Rate of all-cause mortality and ischemic events
Rate of death from any cause + ischemic stroke or peripheral embolism
Rate of Rehospitalisation
Rate of any readmission to a hospital
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Josep Rodes-Cabau
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Sponsor institution